Skip to content

Risk groups for children aged 5–11-years-old

THL (Finnish Institute for Health and Welfare) recommends COVID-19 vaccinations for children aged 5-11-years-old who are at-risk.

Most of the diseases mentioned below are very rare, whereupon the child is then being monitored by a specialist. The attending specialist is best placed to assess whether a child is at-risk.

  1. Obesity
  2. Organ transplant or stem cell transplant
  3. Severe immunosuppressive therapy or immunodeficiency
  4. A chronic pulmonary disease
  5. Heart diseases
  6. Chronic nephropathy
  7. Severe chronic liver disease
  8. Neurological disorders that cause respiratory failure or increase susceptibility to infection
  9. Down syndrome
  10. Type 1 and 2 diabetes
  11. Asthma requiring continuous medication

Obesity

This group includes children with a body mass index (ISO-BMI) of 30 or more.

The body mass index of children (ISO-BMI) takes into account the body proportions of children and their changes with growth and age. The ISO-BMI weight index is calculated by using age, height and weight data, and can be calculated by using the following calculator:

ISO-BMI calculator for children's body mass index (in Finnish)

Minimum weight in full kilograms above the ISO-BMI 30 limit for children of different heights
Minimum weight in full kilograms above the ISO-BMI 30 limit for children of different heights
100 cm 25 kg
110 cm 30 kg
120 cm 36 kg
130 cm 42 kg
140 cm 49 kg
150 cm 56 kg
160 cm 64 kg
170 cm 72 kg

Organ transplant or stem cell transplant

This group includes children who are awaiting an organ transplant or who have had an organ transplant or a stem cell transplant.

Severe immunosuppressive therapy or immunodeficiency

The group includes

  • children who receive treatment that severely impairs their defences. Such treatments include, for example, chemotherapy or some of the treatments for rheumatic, intestinal or neurological diseases, such as high-dose cortisone treatment (e.g. prednisolone 20 mg/day or more, 1 mg/kg or more for those weighing less than 20 kg).
    • The following drugs are not considered to cause severe immunodeficiency: hydroxychloroquine, leflunomide, mycophenolate, azathioprine, methotrexate, infliximab, adalimumab, vedolizumab and ustekinumab.
  • children with a rare metabolic disease or other rare disease that affects the immune system
  • children with severe congenital immunodeficiency
  • children with HIV infection and a CD4 helper cell level of less than 0.350 x 109 cells/l.

A chronic pulmonary disease

This group includes children with any of the following conditions:

  • rare severe lung diseases
  • lung and muscle diseases requiring ventilatory support or supplemental oxygen therapy
  • lung disease with increased pulmonary circulatory resistance (pulmonary hypertension)
  • severely reduced removal of lung mucus (severe bronchiectasis or bronchial dysfunction).

Children in this group are monitored with specialist care.

Heart diseases

This group includes children with heart failure, pulmonary hypertension, or uncut cyanotic Fallot's tetralogy (TOF).

The group also includes children whose pulmonary circulation is dependent on a shunt (BT shunt, RV-PA shunt).

Children in this group are monitored with specialist care.

This group does not include, for example, observable mild heart valve defects and murmurs that have not caused heart failure or pulmonary hypertension.

Chronic nephropathy

This group includes children with kidney disease requiring dialysis, glomerulonephritis, kidney damage related to hypertension or diabetes, or other long-term kidney failure.

Children in this group are monitored with specialist care.

Severe chronic liver disease

This group includes persons with, for example, liver failure, fibrosis and cirrhosis of the liver.

Children in this group are monitored with specialist care.

Neurological disorders that cause respiratory failure or increased susceptibility to infection

This group includes neurological patients with respiratory failure and/or increased susceptibility to infection.

Most often, children in this group are monitored with specialist care.

All children treated in institutions for the mentally handicapped are also at-risk.

This group does not include other paediatric neurological patients, such as patients with headaches, epilepsy, or ADD/ADHD.

Down syndrome

The group includes children with Down syndrome.

Type 1 and 2 diabetes

This group includes children with type 1 diabetes or type 2 diabetes that requires medication.

Asthma requiring continuous medication

The group includes children using daily therapeutic asthma medication. The medication for treatment should be long-lasting, with continuous use for at least 6 months.

This group does not include children who only use opening asthma medication or who only take the medication for a short period of time, for example, in connection with infections.




17.12.2021 09:30